Tokyo-based Ubie, which offers an AI-powered patient symptom questionnaire for medical care guidance, closed a $45M Series C, bringing its total funding to $76M
Jasmine Pennic / HIT Consultant :
Context & Ripple Effects
Ubie's $45M Series C lands it in the middle of a funded cohort of AI symptom-assessment companies: Ada Health raised a $90M Series B in 2021, Infermedica followed with a $30M Series B for symptom analysis and triage in early 2022, and Tokyo neighbor AI Medical Service had already shown Japan can back medical AI at scale with its $42.9M Series B for gastric-cancer detection in 2019.
What distinguishes Ubie is the entry point: a patient-facing questionnaire that guides people to appropriate medical care, rather than a diagnostic tool aimed at clinicians. The round, reported by Jasmine Pennic of HIT Consultant, brings Ubie to $76M total — still well behind Ada Health's $90M single raise, which frames how capital-intensive this category has become.
First-order effects
- Ubie now has the capital to scale its patient questionnaire across more providers and markets, competing head-to-head with Ada Health's symptom-assessment app and Infermedica's triage tools for the same hospital and payer integrations.
- Health systems choosing a front-door triage vendor face a field where the leaders — Ada, Infermedica, Ubie — are all newly capitalized, raising the bar on accuracy claims and integration depth they must demonstrate.
Second-order effects
- As symptom-checker vendors chase provider contracts, pressure builds on adjacent players like Huma Therapeutics — whose $80M Series D for health-app infrastructure targets a similar clinical-workflow layer — to clarify whether they are partners or competitors to triage engines.
- Pricing in patient-triage software trends toward bundled care-navigation contracts rather than per-app licenses, since Ubie's questionnaire only has value if it routes patients into a health system's booked capacity.
Third-order effects
- If the funding pattern holds, AI symptom assessment is consolidating from consumer wellness apps into infrastructure embedded at the front door of health systems, with a handful of well-capitalized vendors — Ada, Ubie, Infermedica — setting the standard for how patients enter care.
- For Japan specifically, Ubie's round extends the precedent set by AI Medical Service, suggesting a domestic medical-AI sector capable of producing venture-scale companies alongside the US and European players rather than importing them.
The trend: AI symptom-assessment companies are attracting successive large venture rounds as the category shifts from standalone consumer apps to triage infrastructure embedded in health systems.